NOX1 deficiency in apolipoprotein E-knockout mice is associated with elevated plasma lipids and enhanced atherosclerosis

Free Radical Research

Volumn 49, Issue 2, 2015, Pages 186-198

  Sobey, C G ^a   Judkins, C P ^a   Rivera, J ^a   Lewis, C V ^a   Diep, H ^a   Lee, H W ^a   Kemp Harper, B K ^a   Broughton, B R S ^a   Selemidis, S ^a   Gaspari, T A ^a   Samuel, C S ^a   Drummond, G R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Aortic lesions; Collagen; NADPH oxidase; Superoxide; Vascular smooth muscle cells

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN; GELATINASE B; LIPID; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DESCENDING AORTA; ENZYME DEFICIENCY; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE; ANIMAL; BLOOD; GENETICS;

MUS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MICE; MICE, KNOCKOUT; NADH, NADPH OXIDOREDUCTASES; TRIGLYCERIDES;

EID: 84926612601     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2014.992893     Document Type: Article

References (49)

1. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
2. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 2008; 120: 254-91.
3. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011; 10: 453-71.
4. Morawietz H, Weber M, Rueckschloss U, Lauer N, Hacker A, Kojda G. Upregulation of vascular NAD(P)H oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem Biophys Res Commun 2001; 285: 1130-5.
5. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90: E58-65.
6. Wendt MC, Daiber A, Kleschyov AL, Mulsch A, Sydow K, Schulz E, et al. Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. Free Radic Biol Med 2005; 39: 381-91.
7. Fenyo IM, Florea IC, Raicu M, Manea A. Tyrphostin AG490 reduces NAPDH oxidase activity and expression in the aorta of hypercholesterolemic apolipoprotein E-deficient mice. Vascul Pharmacol 2011; 54: 100-6.
8. Stanic B, Pandey D, Fulton DJ, Miller FJ Jr. Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2452-60.
9. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429-35.
10. Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 2010; 298: H24-32.
11. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001; 88: 947-53.
12. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004; 109: 1795-801.
13. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005; 112: 2677-85.
14. Gavazzi G, Banfi B, Deffert C, Fiette L, Schappi M, Herrmann F, Krause KH. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 2006; 580: 497-504.
15. Brait VH, Jackman KA, Walduck AK, Selemidis S, Diep H, Mast AE, et al. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab 2010; 30: 1306-17.
16. Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond GR, Sobey CG. Reduction of cerebral infarct volume by apocynin requires pretreatment and is absent in Nox2-deficient mice. Br J Pharmacol 2009; 156: 680-8.
17. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010; 8.
18. Kim HA, Brait VH, Lee S, De Silva TM, Diep H, Eisenhardt A, et al. Brain infarct volume after permanent focal ischemia is not dependent on Nox2 expression. Brain Res 2012; 1483: 105-11.
19. Kahles T, Kohnen A, Heumueller S, Rappert A, Bechmann I, Liebner S, et al. NADPH oxidase Nox1 contributes to ischemic injury in experimental stroke in mice. Neurobiol Dis 2010; 40: 185-92.
20. Jackman KA, Miller AA, Drummond GR, Sobey CG. Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke. Brain Res 2009; 1286: 215-220.
21. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 2001; 108: 1513-1522.
22. Vendrov AE, Hakim ZS, Madamanchi NR, Rojas M, Madamanchi C, Runge MS. Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler Thromb Vasc Biol 2007; 27: 2714-2721.
23. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2000; 20: 1529-1535.
24. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108.
25. Miller AA, De Silva TM, Judkins CP, Diep H, Drummond GR, Sobey CG. Augmented superoxide production by Nox2-containing NADPH oxidase causes cerebral artery dysfunction during hypercholesterolemia. Stroke 2010; 41: 784-789.
26. Woessner JF Jr. Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 1995; 248: 510-528.
27. Ambasta RK, Schreiber JG, Janiszewski M, Busse R, Brandes RP. Noxa1 is a central component of the smooth muscle NADPH oxidase in mice. Free Radic Biol Med 2006; 41: 193-201.
28. Xu S, Chamseddine AH, Carrell S, Miller FJ Jr. Nox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaques. Redox Biol 2014; 2: 642-650.
29. Ago T, Kitazono T, Kuroda J, Kumai Y, Kamouchi M, Ooboshi H, et al. NAD(P)H oxidases in rat basilar arterial endothelial cells. Stroke 2005; 36: 1040-1046.
30. Zhao R, Ma X, Xie X, Shen GX. Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Am J Physiol Endocrinol Metab 2009; 297: E104-E111.
31. Lee CF, Qiao M, Schroder K, Zhao Q, Asmis R. Nox4 is a novel inducible source of reactive oxygen species in monocytes and macrophages and mediates oxidized low density lipoproteininduced macrophage death. Circ Res 2010; 106: 1489-1497.
32. Chen CY, Yi L, Jin X, Zhang T, Fu YJ, Zhu JD, et al. Inhibitory effect of delphinidin on monocyte-endothelial cell adhesion induced by oxidized low-density lipoprotein via ROS/p38MAPK/NF-kappaB pathway. Cell Biochem Biophys 2011; 61: 337-348.
33. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006; 12: 1075-1080.
34. Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, Bennett MR. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 2008; 102: 1529-1538.
35. Zimmerman MC, Takapoo M, Jagadeesha DK, Stanic B, Banfi B, Bhalla RC, Miller FJ Jr. Activation of NADPH oxidase 1 increases intracellular calcium and migration of smooth muscle cells. Hypertension 2011; 58: 446-453.
36. Jagadeesha DK, Takapoo M, Banfi B, Bhalla RC, Miller FJ Jr. Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc Res 2012; 93: 406-413.
37. Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, et al. Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol 2012; 303: H282-H296.
38. Bruder-Nascimento T, Chinnasamy P, Riascos-Bernal DF, Cau SB, Callera GE, Touyz RM, et al. Angiotensin II induces Fat1 expression/activation and vascular smooth muscle cell migration via Nox1-dependent reactive oxygen species generation. J Mol Cell Cardiol 2014; 66: 18-26.
39. Niu XL, Madamanchi NR, Vendrov AE, Tchivilev I, Rojas M, Madamanchi C, et al. Nox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. Circulation 2010; 121: 549-559.
40. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, et al. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002; 22: 21-27.
41. Xu S, Shriver AS, Jagadeesha DK, Chamseddine AH, Szocs K, Weintraub NL, et al. Increased expression of Nox1 in neointimal smooth muscle cells promotes activation of matrix metalloproteinase-9. J Vasc Res 2012; 49: 242-248.
42. Lai CF, Seshadri V, Huang K, Shao JS, Cai J, Vattikuti R, et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 2006; 98: 1479-1489.
43. Jiang S, Streeter J, Schickling BM, Zimmerman K, Weiss RM, Miller FJ Jr. Nox1 NADPH oxidase is necessary for late but not early myocardial ischaemic preconditioning. Cardiovasc Res 2014; 102: 79-87.
44. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112: 2668-2676.
45. Youn JY, Gao L, Cai H. The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes. Diabetologia 2012; 55: 2069-2079.
46. Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013; 127: 1888-1902.
47. Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, Miller FJ Jr. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 2011; 216: 321-326.
48. Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH, et al. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology 2011; 53: 1730-1741.
49. Cui W, Matsuno K, Iwata K, Ibi M, Matsumoto M, Zhang J, et al. NOX1/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Hepatology 2011; 54: 949-958.